Robbins Geller Wins Second Circuit Appeal and Revives Antitrust Case Against Goldman Sachs and JPMorgan
On August 27, 2019, the United States Court of Appeals for the Second Circuit ruled in plaintiffs’ favor in Ampal Inc., Claridge Products and Equipment, Inc., Custom Aluminum Products Inc. and Extruded Aluminum Corp. v. Goldman Sachs Group, Inc., reversing the district court’s dismissal of the consolidated antitrust action.
In disagreeing with the prior judgment made by the United States District Court for the Southern District of New York, the Second Circuit reversed the dismissal of the aluminum purchasers’ antitrust claims that Goldman Sachs, JPMorgan Chase, mining company Glencore, and other companies conspired to drive up prices for metal by reducing supply.
The case alleges that the defendants, “having acquired large positions in primary aluminum at low prices during the economic downturn following the 2008 market collapse in anticipation of future price increases, conspired with each other and with the [w]arehousing [d]efendants to inflate artificially the prices they would realize in the sale of these positions by manipulating the Midwest Premium.”
The Second Circuit ruled that the district court was mistaken to compare the case to an earlier August 2016 decision made in In re Aluminum Warehousing Antitrust Litig., 833 F.3d 151 (2d Cir. 2016) (“Aluminum III”), where the claims were dismissed because the claimed injuries were too removed from the alleged misconduct. “The circumstances of these plaintiffs differ materially from those involved in Aluminum III, and the rationale of Aluminum III does not apply to their complaints. In our view, they have adequately pleaded antitrust injury. We therefore vacate the judgment of dismissal,” stated the Second Circuit.
The previous judgment is vacated and the case remanded.
Ampal Inc., Claridge Products and Equipment, Inc., Custom Aluminum Products Inc. and Extruded Aluminum Corp. v. Goldman Sachs Group, Inc., Nos. 16-4230, 16-4233, 16-4235, 16-4243, 16-4305, and 16-4308, Opinion (2d Cir. Aug. 27, 2019).
Read More Firm News
- May 16, 2022
- “Catastrophic” – San Francisco Public Health Department Doctor Describes the City’s Struggle with the Opioid CrisisMay 11, 2022
- May 10, 2022
- “Their Ultimate Concern Was to Drive Sales”: Partner Aelish Baig and Co-Counsel Present Case Against Pharmaceutical CompaniesApril 27, 2022
- April 26, 2022